479 related articles for article (PubMed ID: 35223476)
1. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
Front Oncol; 2022; 12():795933. PubMed ID: 35223476
[TBL] [Abstract][Full Text] [Related]
2. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
3. The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Nan Z; Guoqing W; Xiaoxu Y; Yin M; Xin H; Xue L; Rong W
Biomed Res Int; 2021; 2021():1780860. PubMed ID: 33791360
[TBL] [Abstract][Full Text] [Related]
4. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
Front Oncol; 2019; 9():1161. PubMed ID: 31750249
[No Abstract] [Full Text] [Related]
5. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Chen X; Fang L; Zhu Y; Bao Z; Wang Q; Liu R; Sun W; Du H; Lin J; Yu B; Chen S; Zhou J; Zhou J
Cancer Immunol Immunother; 2021 Dec; 70(12):3513-3524. PubMed ID: 33899131
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of tumor mutation burden on survival of gastric cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Ke L; Li S; Huang D
Int Immunopharmacol; 2023 Nov; 124(Pt B):110986. PubMed ID: 37748223
[TBL] [Abstract][Full Text] [Related]
9. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Kim JY; Kronbichler A; Eisenhut M; Hong SH; van der Vliet HJ; Kang J; Shin JI; Gamerith G
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31731749
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
Meng G; Liu X; Ma T; Lv D; Sun G
PLoS One; 2022; 17(2):e0263629. PubMed ID: 35113949
[TBL] [Abstract][Full Text] [Related]
11. ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
Nie W; Wang ZJ; Zhang K; Li B; Cai YR; Wen FC; Zhang D; Bai YZ; Zhang XY; Wang SY; Cheng L; Zhong H; Liu L; Wang J; Han BH
BMC Med; 2022 May; 20(1):170. PubMed ID: 35509036
[TBL] [Abstract][Full Text] [Related]
12. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis.
Cao J; Yang X; Chen S; Wang J; Fan X; Fu S; Yang L
Transl Oncol; 2022 Jun; 20():101375. PubMed ID: 35339028
[TBL] [Abstract][Full Text] [Related]
13. The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis.
Ning B; Liu Y; Wang M; Li Y; Xu T; Wei Y
Front Pharmacol; 2022; 13():748674. PubMed ID: 35355708
[No Abstract] [Full Text] [Related]
14. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
Front Immunol; 2021; 12():751407. PubMed ID: 34659255
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Li LL; Yu CF; Xie HT; Chen Z; Jia BH; Xie FY; Cai YF; Xue P; Zhu SJ
Cancer Med; 2023 May; 12(10):11211-11233. PubMed ID: 37161541
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer.
Wei J; Feng J; Weng Y; Xu Z; Jin Y; Wang P; Cui X; Ruan P; Luo R; Li N; Peng M
Front Oncol; 2021; 11():706910. PubMed ID: 34660274
[TBL] [Abstract][Full Text] [Related]
18. The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis.
Ke L; Li S; Cui H
BMC Cancer; 2022 Nov; 22(1):1185. PubMed ID: 36397030
[TBL] [Abstract][Full Text] [Related]
19. Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis.
Wan L; Wang Z; Xue J; Yang H; Zhu Y
Transl Cancer Res; 2020 Sep; 9(9):5437-5449. PubMed ID: 35117909
[TBL] [Abstract][Full Text] [Related]
20. Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
Wang Z; Duan J; Wang G; Zhao J; Xu J; Han J; Zhao Z; Zhao J; Zhu B; Zhuo M; Sun J; Bai H; Wan R; Wang X; Fei K; Wang S; Zhao X; Zhang Y; Huang M; Huang D; Qi C; Gao C; Bai Y; Dong H; Xiong L; Tian Y; Wang D; Xu C; Wang W; Li J; Hu X; Cai S; Wang J
J Thorac Oncol; 2020 Apr; 15(4):556-567. PubMed ID: 31843683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]